Project:

Analysis of complement activation by EIA

<table>
<thead>
<tr>
<th>AUTHORED BY:</th>
<th>DATE:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neill Liptrott</td>
<td>12.02.2016</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>REVIEWED BY:</th>
<th>DATE:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthias Roesslein</td>
<td>18.02.2016</td>
</tr>
<tr>
<td>Matthias Roesslein</td>
<td>30.03.2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>APPROVED BY:</th>
<th>DATE:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthias Roesslein</td>
<td>30.03.2017</td>
</tr>
</tbody>
</table>

**DOCUMENT HISTORY**

<table>
<thead>
<tr>
<th>Effective Date</th>
<th>Date Revision Required</th>
<th>Supersedes</th>
</tr>
</thead>
<tbody>
<tr>
<td>DD/MM/YYYY</td>
<td>DD/MM/YYYY</td>
<td>DD/MM/YYYY</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Version</th>
<th>Approval Date</th>
<th>Description of the Change</th>
<th>Author / Changed by</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>12.02.2016</td>
<td>All Initial Document</td>
<td>Neill Liptrott</td>
</tr>
<tr>
<td>1.3</td>
<td>30.03.2017</td>
<td>All Additions and small corrections</td>
<td>Neill Liptrott</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Document Type</th>
<th>Document ID</th>
<th>Version</th>
<th>Status</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOP</td>
<td>EUNCL-ITA-005.2</td>
<td>1.3</td>
<td></td>
<td>1/13</td>
</tr>
</tbody>
</table>
Table of Content

1 Introduction ........................................................................................................................................3
2 Principle of the Method .......................................................................................................................3
3 Applicability and Limitations (Scope) .................................................................................................4
4 Related Documents .............................................................................................................................4
5 Equipment and Reagents ...................................................................................................................5
   5.1 Equipment.....................................................................................................................................5
   5.2 Reagents .......................................................................................................................................5
   5.3 Materials .......................................................................................................................................6
   5.4 Reagent Preparation ......................................................................................................................6
   5.5 Preparation of Study samples .......................................................................................................8
   5.6 Plasma collection and storage .....................................................................................................9
      5.6.1 Fresh volunteer blood ...........................................................................................................9
      5.6.2 Commerically supplied blood .............................................................................................9
6 Procedure ............................................................................................................................................9
   6.1 General remarks ...........................................................................................................................9
   6.2 Experimental procedure ..............................................................................................................10
   6.3 Flow chart ....................................................................................................................................11
   6.4 Data analysis ..............................................................................................................................11
7 Quality Control, Quality Assurance, Acceptance Criteria .................................................................12
8 Health and Safety Warnings, Cautions and Waste Treatment .........................................................12
9 Abbreviations ....................................................................................................................................12
10 References.........................................................................................................................................12
1 Introduction
This document describes a protocol for quantitative determination of complement activation by an Enzyme Immunoassay (EIA). The complement system represents an innate arm of immune defense and is named so because it “complements” the antibody-mediated immune response. Three major pathways leading to complement activation have been described: they are the classical pathway, alternative pathway and lectin pathway (Figure 1). The classical pathway is activated by immune (antigen-antibody) complexes. Activation of the alternative pathway is antibody independent. The lectin pathway is initiated by plasma protein mannose-binding lectin.

The complement system is composed of several components (C1, C2, ..., C9), and Factors (B, D, H, I, and P). Activation of any of the three pathways results in cleavage of the C3 component of the complement system [1, 2].

2 Principle of the Method
In the protocol presented herein, human plasma is exposed to a test material and subsequently analyzed by EIA for the presence of the complement components C4d, iC3b and Bb. The antibodies specific to these proteins are immobilized on 96 well plates and are obtained from commercial suppliers. Test nanoparticles found to be positive in the qualitative western blot assay are then subject to a more detailed investigation aimed at delineation of the specific complement activation pathway. Detection of elevated levels of C4d protein is indicative of complement activation via the classical or lectin pathway. Elevation in Bb levels is a sign of alternative pathway activation. Estimation of iC3b levels is used to confirm, in a more accurate, quantitative way, the results of the initial western blot screen specific to the C3 component of the complement system.
Figure 1. Complement activation pathways. (This illustration is reproduced from reference 1 with permission from EMD Biosciences, Inc.)

3 Applicability and Limitations (Scope)
The purpose of this assay is to determine complement activation by nanoparticles. Delineation of the specific pathway activated is completed using assays measuring either C4d or Bb which measure activation of the classical/lectin pathway and the alternative pathway respectively. Nanoparticles which may absorb within the assay range of the EIA should be treated with caution due to interference. Inhibition/enhancement controls should always be included.

4 Related Documents
Table 1:

<table>
<thead>
<tr>
<th>Document ID</th>
<th>Document Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUNCL-ITA-005.2</td>
<td>SOP</td>
</tr>
</tbody>
</table>
5 Equipment and Reagents

5.1 Equipment

5.1.1 Microcentrifuge

5.1.2 Centrifuge capable of running at 2500 x g, with a swinging basket set up to hold 5cc vacutainer tubes

5.1.3 Refrigerator, 2-8°C

5.1.4 Freezer, -20°C

5.1.5 Vortex

5.1.6 Incubator, 37°C

5.1.7 Plate reader capable of operating at 405 nm

5.2 Reagents

5.2.1 Sterile Ca²⁺/Mg²⁺-free phosphate buffered saline (PBS) (Sigma, D8537)

5.2.2 Cobra Venom Factor (positive control) (Quidel Corp., A600)

5.2.3 Veronal Buffer (Boston BioProducts, IBB-260)

5.2.4 Pooled human plasma, anti-coagulated with Sodium citrate

5.2.5 MicroVue iC3b EIA kit (Quidel Corp., A006)

5.2.6 MicroVue C4d fragment EIA kit (Quidel Corp., A0008)

5.2.7 MicroVue Bb Plus EIA kit (Quidel Corp., A027)

5.2.9 Doxil (Doxorubicin HCl, liposome, injection); this is prescription medication available from licensed pharmacy; this drug may not be available to some research laboratories

5.2.10 Cremophor, (Sigma, C 5135)

5.2.11 Complement activator (Quidel, 
https://www.quidel.com/research/complement-reagents/complement-activator)
5.2.12. Taxol (Paclitaxel in Cremophor EL); this is prescription medication available from licensed pharmacy; this drug may not be available to some research laboratories

5.3 Materials

5.3.1 Pipettes covering the range from 0.05 to 1 mL

5.3.2 Microcentrifuge tubes, 1.5 mL

5.3.3 Pipet tips, 0.5 μL – 1.0 mL

5.3.4 Multichannel (8-12 channel) pipettor with volumes 50-300 μL

5.3.5 15 and 50 mL conical tubes

5.3.6 Reagent reservoirs

5.4 Reagent Preparation

5.4.1 Positive Control 1 (Traditional substance known to activate complement)

*Cobra Venom Factor (CVF)* is supplied frozen solution. Thaw this stock, prepare single use aliquots and store them at a nominal temperature of -80°C as long as performance is acceptable. Avoid repeated freeze/thaw cycles. After thawing single use aliquot and using it in the assay, discard any leftover material. For this experiment, use 30 μL (1.1-50 U) of CVF solution. This control activates complement system through alternative pathway.

*Heat Aggregated Gamma Globulin (HAGG)* acts similarly to naturally occurring immune complexes and is very potent activator of complement through the classical pathway. This control is available from Quidel under name “Complement Activator”. Handling and storage are according to the manufacturer’s instructions. Avoid repeated freeze/thaw cycles when stored at -20 °C.

5.4.2 Positive Control 2 (nanoparticle relevant)

*Cremophor-EL* is an excipient commonly used in pharmaceutical industry to dissolve hydrophobic drugs. Cremophor-EL is a nanosized micelle which is known to induce complement activation related pseudoallergy (CARPA) syndrome [2], and therefore is used as a nanoparticle relevant control. The following procedure can be used to
prepare Cremophor-EL with the composition similar to that of clinical formulation of Paclitaxel (Taxol) (527 mg of purified Cremophor® EL* (polyoxyethylated castor oil) and 49.7% (v/v) dehydrated alcohol, USP and 2mg of citric acid per 1mL). Store at room temperature.

To prepare Cremophor-EL mix commercial Cremophor 1:1 with ethanol containing 2 mg/mL of citric acid to mimic the concentration of Cremophor-EL, citric acid, and ethanol used in Taxol® and the generic formulation of paclitaxel.

*Cremophor-EL formulated Paclitaxel (Taxol) can be used an alternative for nanoparticle relevant positive control. It is supplied at a stock concentration 6mg/mL of paclitaxel. When used in this assay the final concentration of Paclitaxel is 2mg/mL. Store 2-8ºC.

PEGylated liposomal doxorubicin (Doxil) can also be used as nanoparticle relevant positive control [3]. Doxil is Doxorubicin formulated in nanoliposomes. It is available through the pharmacy as 20 mg of Doxorubicin HCl in 10 mL vehicle. Store 2-8ºC.

5.4.3 Inhibition/Enhancement Control

Use Positive control sample after the incubation. Prior to loading this sample onto ELISA plate add nanoparticles at the same final concentrations as in the study samples. For example, one can mix 20 μL of the positive control sample and 10 μL of the test nanoparticle. The test result for this sample needs to be adjusted by the dilution factor 1.5 prior to comparison of the test value to the test value of the positive control sample. If the test results are different no more than 25%, the test nanoparticle at the given concentration does not interfere with detection of the complement split product by ELISA.

5.4.4 Negative Control (PBS)

Sterile Ca²⁺/Mg²⁺ free PBS is used as a negative control. Store at room temperature for up to 6 months.

5.4.5 Vehicle Control (relevant to the given nanoparticle)

When nanoparticles are formulated not in saline or PBS, the vehicle sample should be tested to estimate the effect of excipients on the complement system. This control is
specific to each given nanoparticle sample. It should be prepared to match the formulation buffer of the nanoparticle by both the composition and the concentration.

5.5 Preparation of Study samples

This assay requires 400 µL of nanoparticles in PBS at the concentration 3 times higher than the highest final tested concentration. The concentration is selected based on the plasma concentration of the nanoparticle at the intended therapeutic dose. For the purpose of this protocol this concentration is called “theoretical plasma concentration”. Considerations for estimating theoretical plasma concentration were reviewed elsewhere [4] and are summarized in Box 1 below.

**Box 1. Example Calculation of Nanoparticle concentration for In Vitro Test**

In this example, we assume the mouse dose is known to be 123 mg/kg.

\[
\text{human dose} = \frac{\text{mouse dose}}{12.3} = \frac{123 \text{ mg}}{12.3} = 10 \text{ mg/kg}
\]

Blood volume constitutes approximately 8% of body weight, (e.g. a 70 kg human has approximately 5.6 L (8% of 70) of blood). This allows us to get a very rough estimation of what the maximum blood concentration may be.

\[
\text{in vitro concentration}_{\text{human maxtrix}} = \frac{\text{human dose}}{\text{human blood volume}} = \frac{70 \text{ kg} \times 10 \frac{\text{mg}}{\text{kg}}}{5.6 \text{ L}}
\]

\[
= \frac{700 \text{ mg}}{5.6 \text{ L}} = 0.125 \text{ mg/mL}
\]

The assay will evaluate 4 concentrations: 10 X (or when feasible 100X, 30X or 5X) of the theoretical plasma concentration, theoretical plasma concentration and two 1:5 serial dilutions of the theoretical plasma concentration. When the intended therapeutic concentration is unknown, the highest final concentration is 1 mg/mL or the highest reasonably achievable concentration.

For example, if the final theoretical plasma concentration to be tested is 0.2 mg/mL, then a stock of 6 mg/mL will be prepared and diluted 10-fold (0.6 mg/mL), followed by two 1:5 serial dilutions (0.12 and 0.024 mg/mL). When 0.1 mL of each of these samples is added to the test tube and mixed with 0.1 mL of plasma and 0.1 mL of veronal buffer, the final nanoparticle concentrations tested in the assay are: 2.0, 0.2, 0.04 and 0.008 mg/mL.
5.6 Plasma collection and storage

5.6.1 Fresh volunteer blood

Blood is drawn into vacutainer tubes containing anticoagulant. Sodium citrate is ideal anticoagulant for this assay, however depending on phlebotomy paraphernalia plasma anti-coagulated with Sodium citrate may result in high background in the ELISA assay. In this case using K2 EDTA as anticoagulant is acceptable.

The first 5-10 mL of blood should be discarded and not used to prepare plasma. For optimal results, it is important to keep blood at 20-24°C, to avoid exposure to high temperatures (summer time) and low temperatures (winter time), and to avoid prolonged (> 1 h) storage. Blood is transported to the lab in a contained Styrofoam box with warm packs (20-24°C). To prepare plasma, the blood is spun down in a centrifuge 10-minutes at 2500 x g. Plasma is evaluated for the presence of hemolysis. Discoloured plasma (an indication of haemolysis) is not used to prepare the pool. Individual plasma specimens that did not show any indication of hemolysis are pooled and mixed in a conical tube. Plasma must be used for complement testing within 1 hour after collection. Pooled plasma can be used and prepared by mixing plasma from at least 2 individual donors. The assay can also be performed in the plasma from individual donors. In this case analyze plasma from at least 3 donors.

5.6.2 Commerically supplied blood

It is possible to use pooled sodium citrate plasma from commercial suppliers, however, when placing the order, one needs to notify the supplier that the plasma is intended for complement testing so no delays between blood draw and plasma collection occurs. The supplier then freezes the plasma immediately after collection and ships it to the lab on dry ice. When using frozen plasma for the complement activation assay, it is important to avoid repeated freeze/thaw cycles. The frozen plasma should be thawed in a water bath containing ambient tap water, mixed gently and used immediately after thawing. It is also advised to avoid indefinite storage of frozen plasma at -20°C. The sooner the frozen plasma is used, the better the results are. In general, the degree of complement activation estimated by comparing intensity of the C3 split product in the positive control with that of the negative control is greater in fresh plasma than in thawed plasma.

6 Procedure

6.1 General remarks

Ensure the blood to be used in the study has been prepared and handled according to the conditions stated in section 5.6.1.
Dilutions of samples to be run in the EIA should be determined by the end user. An indication of the sufficiency of the dilution can be made by comparing the raw OD values of the test to the negative control. If greater than 2-fold is observed in the test samples, but calculated values are low, then the samples should be tested again at a lower dilution.

6.2 Experimental procedure

6.2.1 In a microcentrifuge tube, combine equal volumes (100 µL of each) of veronal buffer, human plasma, and a test-sample (i.e., positive control, negative control, nanoparticles, or vehicle control if different than PBS). Prepare two replicates of each sample.

6.2.2 Vortex tubes to mix all reaction components, spin briefly in a microcentrifuge to bring any drops down, and incubate in an incubator at a nominal temperature of 37°C for 30 minutes.

6.2.3 Prepare 100 µL aliquots and either use in EIA immediately or freeze at -20ºC for later analysis.

6.2.4 Follow the manufacturer’s instruction to reconstitute complement standard, buffers and controls.

6.2.5 Dilute plasma samples prepared in step 7.3 in complement specimen diluent reagent (provided with each kit). Use the following dilution guide for each individual assay:

- **iC3b** – 1:40 for positive control sample; 1:20 for negative control and other test samples
- **C4d** – 1:30 for all samples
- **Bb** – 1:75 for all samples

*Note: the dilution factors should be determined by each laboratory and adjusted if needed*

6.2.6 Follow manufacturer’s instruction for plate loading volumes, incubation time and plate washing.
6.3 Flow chart

1. Prepare pooled plasma samples
   - Centrifuge, 10 mins @ 2500g
   - Inspect, visually, for signs of haemolysis (discolouration)
   - Pool plasma samples only from viable separations

2. Incubate with controls and test materials
   - Combine equal volumes (100ul) of veronal buffer, plasma and test samples
   - Prepare in duplicate

3. Incubate samples
   - 37°C
   - 30 minutes

4. Reconstitute complement standards, buffers and controls
   - Follow manufacturers guidelines to ensure compliance with latest kit procedures

5. Dilute samples as necessary for analysis
   - Dilution should be determined empirically by the end user
     - As a rough guideline:
       - IC3b – 1:40 for positive control sample, 1:20 for negative control and other test samples
       - C4d – 1:20 for all samples
       - Bb – 1:75 for all samples

6. Run assay
   - Follow manufacturers instruction for loading volumes, incubation times and plate washing to ensure compliance with latest kit requirements.

6.4 Data analysis

Do not forget to use the appropriate dilution factor for control and study samples. Compare determined amount of complement components between positive control or study samples with that in the negative control. An increase in the complement component species 2.0-fold or higher above the background (negative control) constitutes a positive response. If a nanoparticle under study generated a positive response in any of the EIA assays, compare the degree of activation between this particle and the Doxil or other nanoparticle-relevant control. Doxil is used in clinic and is known to induce complement activation related hypersensitivity reactions in sensitive patients [5]. Using Doxil helps to interpret results of this in vitro study for a test nanoparticle. If the degree of activation observed for the test nanoparticle is equal to or greater than that observed for Doxil, this nanoparticle formulation will most likely cause similar or stronger hypersensitivity reactions in patients and may require modifications before entering in vivo preclinical and clinical phases. If the degree of activation is lower than that of Doxil, complement activation should be considered when designing the in vivo evaluation phase for the given particle; but, it is less likely to cause concerns similar to Doxil.
7 Quality Control, Quality Assurance, Acceptance Criteria

7.1 Percent CV between replicates of standard curve, quality controls, and test samples should be within 25%.

7.2 Percent difference from theoretical for each of the standard curve samples should be within 25%, and correlation coefficient should be at or above 0.98.

7.3 Run is acceptable if conditions described in 9.1 and 9.2 are met.

7.4 The degree of complement activation in the positive control sample, estimated by comparing levels of individual complement split product in the positive control with that in the negative controls should be at or above 2.0-fold. Note: cobra venom factor activates complement through the alternative assay, so this control will not provide a positive response in the C4d assay. HAGG is a positive control for C4d assay. Doxil is positive in the C4d EIA.

8 Health and Safety Warnings, Cautions and Waste Treatment

Universal precautions must be used when handling human peripheral blood.

- No sharps are to be used in the preparation of cell isolates of plasma from human healthy volunteer blood.
- All liquid waste must be discarded into 1% Virkon solution and left overnight (18 hours) in a class II BSC with the lid loose to allow for venting.

9 Abbreviations

CVF cobra venom factor
PBS phosphate buffered saline
EIA enzyme immunoassay
IgG (H + L) immunoglobulin G (high and low chains)
NC negative control
PC positive control

10 References
1. EMD Biosciences, C., The Complement System.

